{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:11:40Z","timestamp":1793977900064,"version":"4.8.0"},"reference-count":171,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":143,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cognitive Impairment Associated with Schizophrenia (CIAS) represents one of the core dimensions of Schizophrenia Spectrum Disorders (SSD), with an important negative impact on real-world functional outcomes of people living with SSD. Treatment of CIAS represents a therapeutic goal of considerable importance, and while cognition-oriented evidence-based psychosocial interventions are available, effective pharmacological treatment could represent a game-changer in the lives of people with SSD. The present critical review reports and discusses the evidence regarding the effects of several pharmacological agents that are available in clinical practice or are under study, commenting on both current and future perspectives of CIAS treatment. In particular, the effects on CIAS of antipsychotic medications, anticholinergic medications, benzodiazepines, which are currently commonly used in the treatment of SSD, and of iclepertin, d-serine, luvadaxistat, xanomeline-trospium, ulotaront, anti-inflammatory molecules, and oxytocin, which are undergoing regulatory trials or can be considered as experimental agents, will be reported and discussed. Currently, available pharmacological agents do not appear to provide substantial benefits on CIAS, but accurate management of antipsychotic medications and avoiding treatments that can further exacerbate CIAS represent important strategies. Some molecules that are currently being investigated in Phase 2 and Phase 3 trials have provided very promising preliminary results, but more information is currently required to assess their effectiveness in real-world contexts and to provide clear recommendations regarding their use in clinical practice. The results of ongoing and future studies will reveal whether any of these molecules represents the awaited pharmacological game-changer in the treatment of CIAS.<\/jats:p>","DOI":"10.1093\/schizbullopen\/sgae013","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T01:43:17Z","timestamp":1716342197000},"source":"Crossref","is-referenced-by-count":29,"title":["Pharmacological Treatment of Cognitive Impairment Associated With Schizophrenia: State of the Art and Future Perspectives"],"prefix":"10.1093","volume":"5","author":[{"given":"Antonio","family":"Vita","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Sciences, University of Brescia , Brescia , Italy"},{"name":"Department of Mental Health and Addiction Services, ASST Spedali Civili of Brescia , Brescia , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7570-2195","authenticated-orcid":false,"given":"Gabriele","family":"Nibbio","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, University of Brescia , Brescia , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1784-3915","authenticated-orcid":false,"given":"Stefano","family":"Barlati","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, University of Brescia , Brescia , Italy"},{"name":"Department of Mental Health and Addiction Services, ASST Spedali Civili of Brescia , Brescia , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"issue":"3","key":"2024081205561455800_CIT0001","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/wps.20167","article-title":"The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia","volume":"13","author":"Galderisi","year":"2014","journal-title":"World Psychiatry."},{"issue":"1","key":"2024081205561455800_CIT0002","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/wps.20809","article-title":"The clinical characterization of the patient with primary psychosis aimed at personalization of management","volume":"20","author":"Maj","year":"2021","journal-title":"World Psychiatry."},{"key":"2024081205561455800_CIT0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2023.11.015","article-title":"The schizophrenia syndrome, circa 2024: what we know and how that informs its nature","volume":"264","author":"Tandon","year":"2023","journal-title":"Schizophr Res."},{"issue":"16","key":"2024081205561455800_CIT0004","doi-asserted-by":"crossref","first-page":"7943","DOI":"10.1017\/S0033291723002106","article-title":"Life engagement in people living with schizophrenia: predictors and correlates of patient life engagement in a large sample of people living in the community","volume":"53","author":"Vita","year":"2023","journal-title":"Psychol Med."},{"key":"2024081205561455800_CIT0005","doi-asserted-by":"crossref","first-page":"100249","DOI":"10.1016\/j.scog.2022.100249","article-title":"Cognitive dysfunction in schizophrenia: an expert group paper on the current state of the art","volume":"29","author":"Harvey","year":"2022","journal-title":"Schizophr Res Cogn."},{"key":"2024081205561455800_CIT0006","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/s41380-023-01949-9","article-title":"Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment","volume":"28","author":"McCutcheon","year":"2023","journal-title":"Mol Psychiatry."},{"key":"2024081205561455800_CIT0007","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3389\/fpsyt.2020.00524","article-title":"Autistic symptoms and social cognition predict real-world outcomes in patients with schizophrenia","volume":"11","author":"Deste","year":"2020","journal-title":"Front Psychiatry."},{"issue":"4","key":"2024081205561455800_CIT0008","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1001\/jamapsychiatry.2017.4607","article-title":"Interplay among psychopathologic variables, personal resources, context-related factors, and real-life functioning in individuals with schizophrenia: a network analysis","volume":"75","author":"Galderisi","year":"2018","journal-title":"JAMA Psychiatry."},{"key":"2024081205561455800_CIT0009","doi-asserted-by":"crossref","first-page":"791117","DOI":"10.3389\/fpsyt.2021.791117","article-title":"Improving knowledge on pathways to functional outcome in schizophrenia: main results from the Italian network for research on psychoses","volume":"12","author":"Giuliani","year":"2021","journal-title":"Front Psychiatry."},{"issue":"2","key":"2024081205561455800_CIT0010","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.wpsyc.2012.05.004","article-title":"Predicting the severity of everyday functional disability in people with schizophrenia: cognitive deficits, functional capacity, symptoms, and health status","volume":"11","author":"Harvey","year":"2012","journal-title":"World Psychiatry."},{"key":"2024081205561455800_CIT0011","first-page":"407","article-title":"An update on treatment of cognitive impairment associated with schizophrenia","volume-title":"Cognitive Functioning in Schizophrenia: Leveraging the RDoC Framework. Current Topics in Behavioral Neurosciences","author":"Horan","year":"2023"},{"key":"2024081205561455800_CIT0012","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/YCO.0000000000000925","article-title":"Evidence-based psychosocial interventions in schizophrenia: a critical review","volume":"37","author":"Barlati","year":"2024","journal-title":"Curr Opin Psychiatry."},{"issue":"5","key":"2024081205561455800_CIT0013","doi-asserted-by":"crossref","first-page":"282","DOI":"10.9740\/mhc.2022.10.282","article-title":"Management of cognitive and negative symptoms in schizophrenia","volume":"12","author":"Maroney","year":"2022","journal-title":"Ment Health Clin."},{"issue":"1","key":"2024081205561455800_CIT0014","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1192\/j.eurpsy.2022.2315","article-title":"European Psychiatric Association guidance on treatment of cognitive impairment in schizophrenia","volume":"65","author":"Vita","year":"2022","journal-title":"Eur Psychiatry."},{"issue":"9","key":"2024081205561455800_CIT0015","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","article-title":"The American psychiatric association practice guideline for the treatment of patients with schizophrenia","volume":"177","author":"Keepers","year":"2020","journal-title":"AJP."},{"issue":"2","key":"2024081205561455800_CIT0016","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/wps.21089","article-title":"Long-term efficacy of antipsychotic drugs in initially acutely ill adults with schizophrenia: systematic review and network meta-analysis","volume":"22","author":"Leucht","year":"2023","journal-title":"World Psychiatry."},{"issue":"2","key":"2024081205561455800_CIT0017","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/wps.20994","article-title":"Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors","volume":"21","author":"Correll","year":"2022","journal-title":"World Psychiatry."},{"issue":"5","key":"2024081205561455800_CIT0018","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/schbul\/sbs097","article-title":"Guideline-concordant antipsychotic use and mortality in schizophrenia","volume":"39","author":"Cullen","year":"2013","journal-title":"Schizophr Bull."},{"issue":"1","key":"2024081205561455800_CIT0019","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/wps.20384","article-title":"Excess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas","volume":"16","author":"Liu","year":"2017","journal-title":"World Psychiatry."},{"key":"2024081205561455800_CIT0020","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2147\/NDT.S225643","article-title":"Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment","volume":"16","author":"Correll","year":"2020","journal-title":"Neuropsychiatr Dis Treat."},{"issue":"1","key":"2024081205561455800_CIT0021","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1192\/j.eurpsy.2021.13","article-title":"EPA guidance on treatment of negative symptoms in schizophrenia","volume":"64","author":"Galderisi","year":"2021","journal-title":"Eur Psychiatry."},{"key":"2024081205561455800_CIT0022","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.neubiorev.2021.03.028","article-title":"The effect of antipsychotics on the cognitive performance of individuals with psychotic disorders: network meta-analyses of randomized controlled trials","volume":"126","author":"Baldez","year":"2021","journal-title":"Neurosci Biobehav Rev."},{"issue":"2","key":"2024081205561455800_CIT0023","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/JCP.0000000000001232","article-title":"Safety and efficacy in randomized controlled trials of second-generation antipsychotics versus placebo for cognitive impairments in schizophrenia: a meta-analysis","volume":"42","author":"Ohi","year":"2022","journal-title":"J Clin Psychopharmacol."},{"issue":"4","key":"2024081205561455800_CIT0024","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/schbul\/sbab022","article-title":"A meta-analysis of cognitive remediation for schizophrenia: efficacy and the role of participant and treatment factors","volume":"47","author":"Lejeune","year":"2021","journal-title":"Schizophr Bull."},{"key":"2024081205561455800_CIT0025","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41380-022-01727-z","article-title":"Efficacy and acceptability of psychosocial interventions in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence","volume":"28","author":"Solmi","year":"2022","journal-title":"Mol Psychiatry."},{"issue":"8","key":"2024081205561455800_CIT0026","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1001\/jamapsychiatry.2021.0620","article-title":"Effectiveness, core elements, and moderators of response of cognitive remediation for schizophrenia: a systematic review and meta-analysis of randomized clinical trials","volume":"78","author":"Vita","year":"2021","journal-title":"JAMA Psychiatry."},{"issue":"1","key":"2024081205561455800_CIT0027","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/bjc.12320","article-title":"A meta-analysis of the effects of social-cognitive training in schizophrenia: the role of treatment characteristics and study quality","volume":"61","author":"Yeo","year":"2022","journal-title":"Br J Clin Psychol."},{"issue":"2","key":"2024081205561455800_CIT0028","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3390\/brainsci13020320","article-title":"Impact of physical exercise alone or in combination with cognitive remediation on cognitive functions in people with schizophrenia: a qualitative critical review","volume":"13","author":"Deste","year":"2023","journal-title":"Brain Sci."},{"issue":"3","key":"2024081205561455800_CIT0029","first-page":"546","article-title":"Aerobic exercise improves cognitive functioning in people with schizophrenia: a systematic review and meta-analysis","volume":"43","author":"Firth","year":"2017","journal-title":"Schizophr Bull."},{"key":"2024081205561455800_CIT0030","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.schres.2023.04.012","article-title":"The effect of exercise on global, social, daily living and occupational functioning in people living with schizophrenia: a systematic review and meta-analysis","volume":"256","author":"Korman","year":"2023","journal-title":"Schizophr Res."},{"issue":"1","key":"2024081205561455800_CIT0031","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/wps.21056","article-title":"The future of psychopharmacology: a critical appraisal of ongoing phase 2\/3 trials, and of some current trends aiming to de-risk trial programmes of novel agents","volume":"22","author":"Correll","year":"2023","journal-title":"World Psychiatry."},{"issue":"1","key":"2024081205561455800_CIT0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-022-01904-2","article-title":"Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics","volume":"12","author":"Spark","year":"2022","journal-title":"Transl Psychiatry."},{"issue":"8","key":"2024081205561455800_CIT0033","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s40263-022-00935-z","article-title":"Progress and pitfalls in developing agents to treat neurocognitive deficits associated with schizophrenia","volume":"36","author":"Veselinovi\u0107","year":"2022","journal-title":"CNS Drugs."},{"issue":"10327","key":"2024081205561455800_CIT0034","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(21)01997-8","article-title":"Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis","volume":"399","author":"Schneider-Thoma","year":"2022","journal-title":"Lancet (London, England)."},{"issue":"6","key":"2024081205561455800_CIT0035","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/schbul\/sbs130","article-title":"A systematic review and meta-analysis of recovery in schizophrenia","volume":"39","author":"J\u00e4\u00e4skel\u00e4inen","year":"2013","journal-title":"Schizophr Bull."},{"issue":"3","key":"2024081205561455800_CIT0036","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/schbul\/sbx088","article-title":"The relationship between clinical and personal recovery in patients with schizophrenia spectrum disorders: a systematic review and meta-analysis","volume":"44","author":"Van Eck","year":"2018","journal-title":"Schizophr Bull."},{"issue":"3","key":"2024081205561455800_CIT0037","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/YCO.0000000000000407","article-title":"Recovery from schizophrenia: is it possible","volume":"31","author":"Vita","year":"2018","journal-title":"Curr Opin Psychiatry."},{"issue":"2","key":"2024081205561455800_CIT0038","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00228-013-1600-y","article-title":"Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis","volume":"70","author":"D\u00e9sam\u00e9ricq","year":"2014","journal-title":"Eur J Clin Pharmacol."},{"issue":"3","key":"2024081205561455800_CIT0039","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/acps.12374","article-title":"Second-generation antipsychotic effect on cognition in patients with schizophrenia\u2014a meta-analysis of randomized clinical trials","volume":"131","author":"Nielsen","year":"2015","journal-title":"Acta Psychiatr Scand."},{"issue":"1","key":"2024081205561455800_CIT0040","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1080\/13803395.2018.1488952","article-title":"Comparing the effect of the subcategories of atypical antipsychotic medications on cognition in schizophrenia using a meta-analytic approach","volume":"41","author":"Clissold","year":"2019","journal-title":"J Clin Exp Neuropsychol."},{"issue":"5","key":"2024081205561455800_CIT0041","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2215-0366(21)00039-0","article-title":"Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre\u2013post studies","volume":"8","author":"Kishimoto","year":"2021","journal-title":"Lancet Psychiatry."},{"issue":"9","key":"2024081205561455800_CIT0042","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.euroneuro.2019.06.008","article-title":"Novel antipsychotics specificity profile: a clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone","volume":"29","author":"Corponi","year":"2019","journal-title":"Eur Neuropsychopharmacol."},{"key":"2024081205561455800_CIT0043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eurpsy.2019.01.015","article-title":"The efficacy of cariprazine in negative symptoms of schizophrenia: post hoc analyses of PANSS individual items and PANSS-derived factors","volume":"58","author":"Fleischhacker","year":"2019","journal-title":"Eur Psychiatry."},{"issue":"12","key":"2024081205561455800_CIT0044","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.2174\/1570159X21666230727140843","article-title":"Cognitive effects of lurasidone and cariprazine: a mini systematic review","volume":"21","author":"Olivola","year":"2023","journal-title":"Curr Neuropharmacol."},{"key":"2024081205561455800_CIT0045","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2147\/TCRM.S94060","article-title":"Clinical role of brexpiprazole in depression and schizophrenia","volume":"13","author":"Parikh","year":"2017","journal-title":"TCRM."},{"issue":"5","key":"2024081205561455800_CIT0046","doi-asserted-by":"crossref","first-page":"488","DOI":"10.2174\/138161210790361461","article-title":"Third generation antipsychotic drugs: partial agonism or receptor functional selectivity","volume":"16","author":"Mailman","year":"2010","journal-title":"Curr Pharm Des."},{"issue":"1","key":"2024081205561455800_CIT0047","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/YIC.0000000000000510","article-title":"Differentiating the third generation of antipsychotics: a focus on lumateperone\u2019s similarities and differences","volume":"39","author":"Munayco Maldonado","year":"2024","journal-title":"Int Clin Psychopharmacol."},{"issue":"11","key":"2024081205561455800_CIT0048","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3390\/ph13110365","article-title":"Dopamine, cognitive impairments and second-generation antipsychotics: from mechanistic advances to more personalized treatments","volume":"13","author":"Torrisi","year":"2020","journal-title":"Pharmaceuticals (Basel)."},{"key":"2024081205561455800_CIT0049","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3389\/fphar.2019.00402","article-title":"Treatment-resistant schizophrenia: genetic and neuroimaging correlates","volume":"10","author":"Vita","year":"2019","journal-title":"Front Pharmacol."},{"key":"2024081205561455800_CIT0050","article-title":"A systematic review and meta-analysis of the effect of clozapine on cognitive functions in patients with treatment-resistant schizophrenia [published online ahead of print October 1, 2023]","author":"Cheuk","journal-title":"Schizophr Res."},{"issue":"1","key":"2024081205561455800_CIT0051","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13643-023-02213-5","article-title":"Antipsychotic drugs and their effects on cognitive function: protocol for a systematic review, pairwise, and network meta-analysis","volume":"12","author":"Feber","year":"2023","journal-title":"Syst Rev."},{"issue":"6","key":"2024081205561455800_CIT0052","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/JCP.0000000000000790","article-title":"The impact of medication anticholinergic burden on cognitive performance in people with schizophrenia","volume":"37","author":"Ang","year":"2017","journal-title":"J Clin Psychopharmacol."},{"issue":"10","key":"2024081205561455800_CIT0053","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1038\/s41386-021-01057-8","article-title":"Genome-wide association study accounting for anticholinergic burden to examine cognitive dysfunction in psychotic disorders","volume":"46","author":"Eum","year":"2021","journal-title":"Neuropsychopharmacology."},{"key":"2024081205561455800_CIT0054","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.schres.2017.03.034","article-title":"Cognitive burden of anticholinergic medications in psychotic disorders","volume":"190","author":"Eum","year":"2017","journal-title":"Schizophr Res."},{"issue":"9","key":"2024081205561455800_CIT0055","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1176\/appi.ajp.2020.20081212","article-title":"Anticholinergic medication burden-associated cognitive impairment in schizophrenia","volume":"178","author":"Joshi","year":"2021","journal-title":"AJP."},{"issue":"1","key":"2024081205561455800_CIT0056","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/schbul\/sbaa093","article-title":"The impact of anticholinergic burden on functional capacity in persons with schizophrenia across the adult life span","volume":"47","author":"Khan","year":"2021","journal-title":"Schizophr Bull."},{"key":"2024081205561455800_CIT0057","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.schres.2023.08.015","article-title":"Effect of anticholinergic burden on brain activity during Working Memory and real-world functioning in patients with schizophrenia","volume":"260","author":"Selvaggi","year":"2023","journal-title":"Schizophr Res."},{"issue":"15","key":"2024081205561455800_CIT0058","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1017\/S0033291716002154","article-title":"Anticholinergic burden in schizophrenia and ability to benefit from psychosocial treatment programmes: a 3-year prospective cohort study","volume":"46","author":"O\u2019Reilly","year":"2016","journal-title":"Psychol Med."},{"issue":"9","key":"2024081205561455800_CIT0059","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1176\/appi.ajp.2009.09010017","article-title":"The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia","volume":"166","author":"Vinogradov","year":"2009","journal-title":"Am J Psychiatry."},{"key":"2024081205561455800_CIT0060","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.schres.2019.01.016","article-title":"Verbal learning deficits associated with increased anticholinergic burden are attenuated with targeted cognitive training in treatment refractory schizophrenia patients","volume":"208","author":"Joshi","year":"2019","journal-title":"Schizophr Res."},{"issue":"1","key":"2024081205561455800_CIT0061","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00406-017-0787-9","article-title":"Benzodiazepine long-term administration is associated with impaired attention\/working memory in schizophrenia: results from the national multicentre FACE-SZ data set","volume":"268","author":"Fond","year":"2018","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"issue":"4","key":"2024081205561455800_CIT0062","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1017\/S1041610219000358","article-title":"Benzodiazepine use among older adults with schizophrenia spectrum disorder: prevalence and associated factors in a multicenter study","volume":"32","author":"Schuster","year":"2020","journal-title":"Int Psychogeriatr."},{"issue":"1","key":"2024081205561455800_CIT0063","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00023210-200418010-00004","article-title":"Cognitive effects of long-term benzodiazepine use","volume":"18","author":"Barker","year":"2004","journal-title":"CNS Drugs."},{"issue":"1","key":"2024081205561455800_CIT0064","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.2146\/ajhp160381","article-title":"Benzodiazepine use and cognitive decline in the elderly","volume":"75","author":"Picton","year":"2018","journal-title":"Am J Health Syst Pharm."},{"issue":"Suppl 2","key":"2024081205561455800_CIT0065","first-page":"9","article-title":"The effects of benzodiazepines on cognition","volume":"66","author":"Stewart","year":"2005","journal-title":"J Clin Psychiatry."},{"issue":"7","key":"2024081205561455800_CIT0066","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1001\/jamapsychiatry.2017.0624","article-title":"Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence","volume":"74","author":"Correll","year":"2017","journal-title":"JAMA Psychiatry."},{"key":"2024081205561455800_CIT0067","doi-asserted-by":"crossref","first-page":"110637","DOI":"10.1016\/j.pnpbp.2022.110637","article-title":"Candidates for drug repurposing to address the cognitive symptoms in schizophrenia","volume":"120","author":"Koch","year":"2023","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"issue":"5","key":"2024081205561455800_CIT0068","first-page":"CD011943","article-title":"Mirtazapine adjunct for people with schizophrenia","volume":"2018","author":"Perry","year":"2018","journal-title":"Cochrane Database Syst Rev."},{"issue":"2","key":"2024081205561455800_CIT0069","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.schres.2014.08.015","article-title":"Antidepressants for cognitive impairment in schizophrenia\u2014a systematic review and meta-analysis","volume":"159","author":"Vernon","year":"2014","journal-title":"Schizophr Res."},{"issue":"4","key":"2024081205561455800_CIT0070","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/JCP.0000000000001245","article-title":"Adjunctive fluvoxamine for schizophrenia: a meta-analysis of randomized double-blind, placebo-controlled trials","volume":"40","author":"Zheng","year":"2020","journal-title":"J Clin Psychopharmacol."},{"key":"2024081205561455800_CIT0071","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jpsychires.2019.02.024","article-title":"Adjunctive ondansetron for schizophrenia: a systematic review and meta-analysis of randomized controlled trials","volume":"113","author":"Zheng","year":"2019","journal-title":"J Psychiatr Res."},{"key":"2024081205561455800_CIT0072","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.schres.2019.05.006","article-title":"Co-treatment of buspirone with atypical antipsychotic drugs (AAPDs) improved neurocognitive function in chronic schizophrenia","volume":"209","author":"Wang","year":"2019","journal-title":"Schizophr Res."},{"issue":"1","key":"2024081205561455800_CIT0073","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.euroneuro.2017.11.007","article-title":"Adjunctive azapirone for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials","volume":"28","author":"Zheng","year":"2018","journal-title":"Eur Neuropsychopharmacol."},{"issue":"1","key":"2024081205561455800_CIT0074","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41537-017-0043-3","article-title":"The effect of raloxifene augmentation in men and women with a schizophrenia spectrum disorder: a systematic review and meta-analysis","volume":"4","author":"de Boer","year":"2018","journal-title":"Npj Schizophr."},{"key":"2024081205561455800_CIT0075","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.psyneuen.2018.10.001","article-title":"Raloxifene as a treatment for cognition in women with schizophrenia: the influence of menopause status","volume":"100","author":"Gurvich","year":"2019","journal-title":"Psychoneuroendocrinology."},{"issue":"6","key":"2024081205561455800_CIT0076","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s00406-019-01079-w","article-title":"Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a 24-week double-blind, randomized, parallel, placebo-controlled trial","volume":"270","author":"Huerta-Ramos","year":"2020","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"issue":"5","key":"2024081205561455800_CIT0077","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/JCP.0000000000001274","article-title":"Adjunctive raloxifene and isradipine improve cognitive functioning in patients with schizophrenia: a Pilot study","volume":"40","author":"Vahdani","year":"2020","journal-title":"J Clin Psychopharmacol."},{"issue":"1","key":"2024081205561455800_CIT0078","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-023-02616-x","article-title":"Metformin improves cognitive impairment in patients with schizophrenia: associated with enhanced functional connectivity of dorsolateral prefrontal cortex","volume":"13","author":"Shao","year":"2023","journal-title":"Transl Psychiatry."},{"issue":"8","key":"2024081205561455800_CIT0079","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/ijnp\/pyy045","article-title":"Anti-dementia drugs for psychopathology and cognitive impairment in schizophrenia: a systematic review and meta-analysis","volume":"21","author":"Kishi","year":"2018","journal-title":"Int J Neuropsychopharmacol."},{"issue":"11","key":"2024081205561455800_CIT0080","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1177\/0269881118805496","article-title":"Cognitive improvement of acetylcholinesterase inhibitors in schizophrenia","volume":"32","author":"Santos","year":"2018","journal-title":"J Psychopharmacol."},{"issue":"6","key":"2024081205561455800_CIT0081","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/JCP.0000000000001115","article-title":"Adjunctive memantine treatment of schizophrenia: a double-blind, randomized Placebo-Controlled Study","volume":"39","author":"Hassanpour","year":"2019","journal-title":"J Clin Psychopharmacol."},{"issue":"3","key":"2024081205561455800_CIT0082","first-page":"258","article-title":"The effect of memantine versus folic acid on cognitive impairment in patients with schizophrenia: a randomized clinical trial","volume":"18","author":"Hosseini","year":"2023","journal-title":"Iran J Psychiatry."},{"issue":"1","key":"2024081205561455800_CIT0083","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1055\/a-0970-9310","article-title":"Acute and long-term memantine add-on treatment to risperidone improves cognitive dysfunction in patients with acute and chronic schizophrenia","volume":"53","author":"Schaefer","year":"2020","journal-title":"Pharmacopsychiatry."},{"issue":"13","key":"2024081205561455800_CIT0084","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1038\/s41386-020-00865-8","article-title":"Memantine effects on auditory discrimination and training in schizophrenia patients","volume":"45","author":"Swerdlow","year":"2020","journal-title":"Neuropsychopharmacol."},{"issue":"1","key":"2024081205561455800_CIT0085","first-page":"1","article-title":"Galantamine for Alzheimer\u2019s disease and mild cognitive impairment","volume":"2009","author":"Loy","year":"2006","journal-title":"Cochrane Database Syst Rev."},{"issue":"2","key":"2024081205561455800_CIT0086","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1527-3458.2002.tb00221.x","article-title":"Galantamine\u2014a Novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer\u2019s Disease","volume":"8","author":"Lilienfeld","year":"2002","journal-title":"CNS Drug Rev."},{"key":"2024081205561455800_CIT0087","doi-asserted-by":"crossref","first-page":"113285","DOI":"10.1016\/j.psychres.2020.113285","article-title":"Meta-analysis of randomized controlled trials of galantamine in schizophrenia: significant cognitive enhancement","volume":"291","author":"Koola","year":"2020","journal-title":"Psychiatry Res."},{"key":"2024081205561455800_CIT0088","doi-asserted-by":"crossref","first-page":"113409","DOI":"10.1016\/j.psychres.2020.113409","article-title":"Galantamine\u2013memantine combination in the treatment of Alzheimer\u2019s disease and beyond","volume":"293","author":"Koola","year":"2020","journal-title":"Psychiatry Res."},{"key":"2024081205561455800_CIT0089","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.neuropharm.2012.06.051","article-title":"The NMDA receptor as a target for cognitive enhancement","volume":"64","author":"Collingridge","year":"2013","journal-title":"Neuropharmacology."},{"issue":"19","key":"2024081205561455800_CIT0090","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1111\/bph.13919","article-title":"Glutamatergic regulation of cognition and functional brain connectivity: insights from pharmacological, genetic and translational schizophrenia research","volume":"174","author":"Dauvermann","year":"2017","journal-title":"Br J Pharmacol."},{"issue":"4","key":"2024081205561455800_CIT0091","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/schbul\/sbu171","article-title":"Glutamate networks implicate cognitive impairments in schizophrenia: Genome-Wide Association studies of 52 cognitive phenotypes","volume":"41","author":"Ohi","year":"2015","journal-title":"Schizophr Bull."},{"issue":"5","key":"2024081205561455800_CIT0092","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/pcn.12823","article-title":"Glutamate hypothesis in schizophrenia","volume":"73","author":"Uno","year":"2019","journal-title":"Psychiatry Clin Neurosci."},{"issue":"13","key":"2024081205561455800_CIT0093","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1038\/s41386-021-01070-x","article-title":"Lower cholinergic basal forebrain volumes link with cognitive difficulties in schizophrenia","volume":"46","author":"Avram","year":"2021","journal-title":"Neuropsychopharmacol."},{"key":"2024081205561455800_CIT0094","first-page":"393","article-title":"Cholinergic functioning, cognition, and anticholinergic medication burden in schizophrenia","volume-title":"Cognitive Functioning in Schizophrenia: Leveraging the RDoC Framework. Current Topics in Behavioral Neurosciences","author":"Joshi","year":"2023"},{"key":"2024081205561455800_CIT0095","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.schres.2020.02.001","article-title":"The role of glutamate and GABA in cognitive dysfunction in schizophrenia and mood disorders\u2014a systematic review of magnetic resonance spectroscopy studies","volume":"249","author":"Reddy-Thootkur","year":"2022","journal-title":"Schizophr Res."},{"key":"2024081205561455800_CIT0096","doi-asserted-by":"crossref","first-page":"105010","DOI":"10.1016\/j.neubiorev.2022.105010","article-title":"Neurofunctional correlates of glutamate and GABA imbalance in psychosis: a systematic review","volume":"144","author":"Zahid","year":"2023","journal-title":"Neurosci Biobehav Rev."},{"key":"2024081205561455800_CIT0097","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3389\/fpsyt.2018.00073","article-title":"Neurosteroids in schizophrenia: pathogenic and therapeutic implications","volume":"9","author":"Cai","year":"2018","journal-title":"Front Psychiatry."},{"issue":"3","key":"2024081205561455800_CIT0098","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S2215-0366(14)00122-9","article-title":"Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment","volume":"2","author":"Khandaker","year":"2015","journal-title":"Lancet Psychiatry."},{"key":"2024081205561455800_CIT0099","doi-asserted-by":"crossref","first-page":"892","DOI":"10.3389\/fpsyt.2019.00892","article-title":"Cytokine alterations in schizophrenia: an updated review","volume":"10","author":"Momtazmanesh","year":"2019","journal-title":"Front Psychiatry."},{"issue":"4","key":"2024081205561455800_CIT0100","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/eip.12859","article-title":"Role of inflammation in the pathogenesis of schizophrenia: a review of the evidence, proposed mechanisms and implications for treatment","volume":"14","author":"Mongan","year":"2020","journal-title":"Early Interv Psychiatry."},{"key":"2024081205561455800_CIT0101","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3389\/fnins.2015.00372","article-title":"The role of inflammation in schizophrenia","volume":"9","author":"M\u00fcller","year":"2015","journal-title":"Front Neurosci."},{"issue":"2","key":"2024081205561455800_CIT0102","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jpsychires.2009.07.002","article-title":"Neurocognitive deficits in schizophrenia are associated with alterations in blood levels of neurosteroids: a multiple regression analysis of findings from a double-blind, randomized, placebo-controlled, crossover trial with DHEA","volume":"44","author":"Ritsner","year":"2010","journal-title":"J Psychiatr Res."},{"issue":"1","key":"2024081205561455800_CIT0103","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/s41386-021-01089-0","article-title":"Mechanisms underlying dorsolateral prefrontal cortex contributions to cognitive dysfunction in schizophrenia","volume":"47","author":"Smucny","year":"2022","journal-title":"Neuropsychopharmacol."},{"key":"2024081205561455800_CIT0104","first-page":"907851","article-title":"Schizophrenia and inflammation research: a bibliometric analysis","volume-title":"Front Immunol.","author":"Sun","year":"2022"},{"key":"2024081205561455800_CIT0105","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1007\/s00406-023-01576-z","article-title":"Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia","volume":"273","author":"Rosenbrock","year":"2023","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"key":"2024081205561455800_CIT0106","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.brainresbull.2012.12.002","article-title":"Mechanisms of glycine release, which build up synaptic and extrasynaptic glycine levels: the role of synaptic and non-synaptic glycine transporters","volume":"93","author":"Harsing","year":"2013","journal-title":"Brain Res Bull."},{"issue":"5","key":"2024081205561455800_CIT0107","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1037\/a0016676","article-title":"Deletion of glycine transporter 1 (GlyT1) in forebrain neurons facilitates reversal learning: enhanced cognitive adaptability","volume":"123","author":"Singer","year":"2009","journal-title":"Behav Neurosci."},{"issue":"2","key":"2024081205561455800_CIT0108","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1124\/jpet.121.001071","article-title":"Effects of the glycine transporter-1 inhibitor iclepertin (BI 425809) on sensory processing, neural network function, and cognition in animal models related to schizophrenia","volume":"382","author":"Rosenbrock","year":"2022","journal-title":"J Pharmacol Exp Ther."},{"issue":"6","key":"2024081205561455800_CIT0109","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/cts.12578","article-title":"Evaluation of pharmacokinetics and pharmacodynamics of BI 425809, a Novel GlyT1 inhibitor: translational studies","volume":"11","author":"Rosenbrock","year":"2018","journal-title":"Clin Transl Sci."},{"issue":"2","key":"2024081205561455800_CIT0110","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s13318-017-0440-z","article-title":"Safety, tolerability and pharmacokinetics of oral BI 425809, a glycine transporter 1 inhibitor, in healthy male volunteers: a partially randomised, single-blind, placebo-controlled, First-in-Human Study","volume":"43","author":"Moschetti","year":"2018","journal-title":"Eur J Drug Metab Pharmacokinet."},{"issue":"8","key":"2024081205561455800_CIT0111","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s40261-018-0660-2","article-title":"Multiple rising doses of oral BI 425809, a GlyT1 inhibitor, in young and elderly healthy volunteers: a randomised, double-blind, Phase I Study investigating safety and pharmacokinetics","volume":"38","author":"Moschetti","year":"2018","journal-title":"Clin Drug Investig."},{"issue":"5","key":"2024081205561455800_CIT0112","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.clinthera.2019.03.014","article-title":"Pharmacokinetics of single doses of BI 425809 in Healthy Chinese and Japanese Subjects: a randomized study","volume":"41","author":"Tsuda","year":"2019","journal-title":"Clin Ther."},{"issue":"2","key":"2024081205561455800_CIT0113","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1176\/appi.ajp.2007.07010042","article-title":"The MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity","volume":"165","author":"Nuechterlein","year":"2008","journal-title":"Am J Psychiatry."},{"issue":"3","key":"2024081205561455800_CIT0114","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1176\/appi.ajp.163.3.426","article-title":"The schizophrenia cognition rating scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity","volume":"163","author":"Keefe","year":"2006","journal-title":"Am J Psychiatry."},{"issue":"3","key":"2024081205561455800_CIT0115","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S2215-0366(20)30513-7","article-title":"Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study","volume":"8","author":"Fleischhacker","year":"2021","journal-title":"Lancet Psychiatry."},{"key":"2024081205561455800_CIT0116","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41398-022-02096-5","article-title":"Quantitative electroencephalography parameters as neurophysiological biomarkers of schizophrenia-related deficits: a Phase II substudy of patients treated with iclepertin (BI 425809)","volume":"12","author":"Schultheis","year":"2022","journal-title":"Transl Psychiatry."},{"issue":"4","key":"2024081205561455800_CIT0117","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s40261-020-00893-8","article-title":"Evaluation of the efficacy of BI 425809 pharmacotherapy in patients with schizophrenia receiving computerized cognitive training: methodology for a double-blind, randomized, parallel-group trial","volume":"40","author":"Harvey","year":"2020","journal-title":"Clin Drug Investig."},{"issue":"5","key":"2024081205561455800_CIT0118","doi-asserted-by":"crossref","first-page":"522","DOI":"10.2174\/138161210790361452","article-title":"Strategies to enhance N-methyl-d-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis","volume":"16","author":"Tsai","year":"2010","journal-title":"Curr Pharm Des."},{"issue":"10","key":"2024081205561455800_CIT0119","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/mp.2015.68","article-title":"Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials","volume":"20","author":"Iwata","year":"2015","journal-title":"Mol Psychiatry."},{"issue":"1\u20133","key":"2024081205561455800_CIT0120","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.schres.2010.05.012","article-title":"High dose","volume":"121","author":"Kantrowitz","year":"2010","journal-title":"Schizophr Res."},{"issue":"6","key":"2024081205561455800_CIT0121","doi-asserted-by":"crossref","first-page":"e728","DOI":"10.4088\/JCP.11m07031","article-title":"A multicenter, add-on randomized controlled trial of low-dose","volume":"73","author":"Weiser","year":"2012","journal-title":"J Clin Psychiatry."},{"issue":"3","key":"2024081205561455800_CIT0122","first-page":"492","article-title":"Feasibility, safety, and efficacy of the combination of","volume":"38","author":"D\u2019Souza","year":"2013","journal-title":"Neuropsychopharmacology."},{"issue":"23","key":"2024081205561455800_CIT0123","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.3390\/nu14235142","article-title":"The role of","volume":"14","author":"Nasyrova","year":"2022","journal-title":"Nutrients."},{"key":"2024081205561455800_CIT0124","first-page":"31","article-title":"Expression of","volume":"11","author":"Jagannath","year":"2017","journal-title":"Front Neuroanat."},{"issue":"2","key":"2024081205561455800_CIT0125","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/mp.2009.99","article-title":"The neurobiology of","volume":"15","author":"Verrall","year":"2010","journal-title":"Mol Psychiatry."},{"key":"2024081205561455800_CIT0126","doi-asserted-by":"crossref","first-page":"102947","DOI":"10.1016\/j.ajp.2021.102947","article-title":"Efficacy and safety of add-on sodium benzoate, a","volume":"68","author":"Seetharam","year":"2022","journal-title":"Asian J Psychiatry."},{"issue":"10","key":"2024081205561455800_CIT0127","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1007\/s11064-023-03956-2","article-title":"Luvadaxistat: a novel potent and selective","volume":"48","author":"Fradley","year":"2023","journal-title":"Neurochem Res."},{"issue":"2","key":"2024081205561455800_CIT0128","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.schres.2003.09.011","article-title":"The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery","volume":"68","author":"Keefe","year":"2004","journal-title":"Schizophr Res."},{"issue":"7","key":"2024081205561455800_CIT0129","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/s41386-023-01560-0","article-title":"The","volume":"48","author":"O\u2019Donnell","year":"2023","journal-title":"Neuropsychopharmacol."},{"issue":"12","key":"2024081205561455800_CIT0130","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.tips.2022.09.006","article-title":"Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic","volume":"43","author":"Yohn","year":"2022","journal-title":"Trends Pharmacol Sci."},{"issue":"8","key":"2024081205561455800_CIT0131","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa2017015","article-title":"Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia","volume":"384","author":"Brannan","year":"2021","journal-title":"N Engl J Med."},{"issue":"5","key":"2024081205561455800_CIT0132","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00213-023-06362-2","article-title":"Evidence of trospium\u2019s ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results","volume":"240","author":"Breier","year":"2023","journal-title":"Psychopharmacology (Berl)."},{"issue":"1","key":"2024081205561455800_CIT0133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-022-02254-9","article-title":"Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study","volume":"12","author":"Sauder","year":"2022","journal-title":"Transl Psychiatry."},{"issue":"10422","key":"2024081205561455800_CIT0134","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","article-title":"Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline\u2013trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial","volume":"403","author":"Kaul","year":"2024","journal-title":"Lancet."},{"issue":"24","key":"2024081205561455800_CIT0135","doi-asserted-by":"crossref","first-page":"13185","DOI":"10.3390\/ijms222413185","article-title":"Therapeutic potential of TAAR1 agonists in schizophrenia: evidence from preclinical models and clinical studies","volume":"22","author":"Dedic","year":"2021","journal-title":"Int J Mol Sci."},{"issue":"3","key":"2024081205561455800_CIT0136","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1124\/pr.117.015305","article-title":"Trace amines and their receptors","volume":"70","author":"Gainetdinov","year":"2018","journal-title":"Pharmacol Rev."},{"issue":"7","key":"2024081205561455800_CIT0137","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00406-023-01580-3","article-title":"Review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia","volume":"273","author":"Achtyes","year":"2023","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"issue":"1","key":"2024081205561455800_CIT0138","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41537-021-00190-z","article-title":"Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study","volume":"7","author":"Correll","year":"2021","journal-title":"Npj Schizophr."},{"issue":"16","key":"2024081205561455800_CIT0139","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1056\/NEJMoa1911772","article-title":"A non-D2-receptor-binding drug for the treatment of schizophrenia","volume":"382","author":"Koblan","year":"2020","journal-title":"N Engl J Med."},{"issue":"8","key":"2024081205561455800_CIT0140","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.3390\/brainsci13081193","article-title":"Novel compounds in the treatment of schizophrenia\u2014a selective review","volume":"13","author":"Tsapakis","year":"2023","journal-title":"Brain Sci."},{"issue":"1","key":"2024081205561455800_CIT0141","doi-asserted-by":"crossref","first-page":"10","DOI":"10.9758\/cpn.2020.18.1.10","article-title":"Anti-inflammatory strategies for schizophrenia: a review of evidence for therapeutic applications and drug repurposing","volume":"18","author":"Hong","year":"2020","journal-title":"Clin Psychopharmacol Neurosci."},{"key":"2024081205561455800_CIT0142","first-page":"227","article-title":"Inflammation, antipsychotic drugs, and evidence for effectiveness of anti-inflammatory agents in schizophrenia","volume-title":"Neuroinflammation and Schizophrenia. Current Topics in Behavioral Neurosciences","author":"Pandurangi","year":"2020"},{"issue":"1","key":"2024081205561455800_CIT0143","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/schbul\/sbt139","article-title":"Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update","volume":"40","author":"Sommer","year":"2014","journal-title":"Schizophr Bull."},{"issue":"8","key":"2024081205561455800_CIT0144","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1177\/0004867419835028","article-title":"Adjunctive use of anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials","volume":"53","author":"Cho","year":"2019","journal-title":"Aust N Z J Psychiatry."},{"issue":"14","key":"2024081205561455800_CIT0145","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1017\/S0033291719001995","article-title":"An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis","volume":"49","author":"\u00c7akici","year":"2019","journal-title":"Psychol Med."},{"key":"2024081205561455800_CIT0146","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.bbi.2020.08.028","article-title":"Efficacy and safety of anti-inflammatory agents in treatment of psychotic disorders\u2014a comprehensive systematic review and meta-analysis","volume":"90","author":"Jeppesen","year":"2020","journal-title":"Brain Behav Immun."},{"key":"2024081205561455800_CIT0147","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.neubiorev.2017.04.013","article-title":"The effect of N-acetylcysteine (NAC) on human cognition\u2014a systematic review","volume":"78","author":"Skvarc","year":"2017","journal-title":"Neurosci Biobehav Rev."},{"issue":"5","key":"2024081205561455800_CIT0148","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/0004867419893439","article-title":"Meta-analysis of randomised controlled trials with N-acetylcysteine in the treatment of schizophrenia","volume":"54","author":"Yolland","year":"2020","journal-title":"Aust N Z J Psychiatry."},{"key":"2024081205561455800_CIT0149","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.schres.2019.08.005","article-title":"The effect of minocycline on amelioration of cognitive deficits and pro-inflammatory cytokines levels in patients with schizophrenia","volume":"212","author":"Zhang","year":"2019","journal-title":"Schizophr Res."},{"key":"2024081205561455800_CIT0150","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.schres.2018.10.023","article-title":"The effect of minocycline on symptoms in schizophrenia: results from a randomized controlled trial","volume":"206","author":"Weiser","year":"2019","journal-title":"Schizophr Res."},{"key":"2024081205561455800_CIT0151","doi-asserted-by":"crossref","first-page":"806","DOI":"10.3389\/fpsyt.2020.00806","article-title":"Social cognition in a research domain criteria perspective: a bridge between schizophrenia and autism spectra disorders","volume":"11","author":"Barlati","year":"2020","journal-title":"Front Psychiatry."},{"issue":"1","key":"2024081205561455800_CIT0152","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/npp.2014.120","article-title":"Developmental perspectives on oxytocin and vasopressin","volume":"40","author":"Hammock","year":"2015","journal-title":"Neuropsychopharmacology."},{"issue":"4","key":"2024081205561455800_CIT0153","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.yfrne.2009.05.004","article-title":"Oxytocin and the neural mechanisms regulating social cognition and affiliative behavior","volume":"30","author":"Ross","year":"2009","journal-title":"Front Neuroendocrinol."},{"issue":"4","key":"2024081205561455800_CIT0154","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40473-020-00214-5","article-title":"The role of intranasal oxytocin on social cognition: an integrative human lifespan approach","volume":"7","author":"Horta","year":"2020","journal-title":"Curr Behav Neurosci Rep."},{"key":"2024081205561455800_CIT0155","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.psyneuen.2017.09.022","article-title":"Intranasal oxytocin, social cognition and neurodevelopmental disorders: a meta-analysis","volume":"87","author":"Keech","year":"2018","journal-title":"Psychoneuroendocrinology."},{"issue":"1","key":"2024081205561455800_CIT0156","first-page":"e190001","article-title":"The effect of intranasal oxytocin on measures of social cognition in schizophrenia: a negative report","volume":"4","author":"Lee","year":"2019","journal-title":"J Psychiatr Brain Sci."},{"key":"2024081205561455800_CIT0157","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2019.00930","article-title":"Oxytocin as treatment for social cognition, not there yet","volume":"10","author":"Erdozain","year":"2020","journal-title":"Front Psychiatry."},{"issue":"2","key":"2024081205561455800_CIT0158","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3390\/pharmaceutics14020323","article-title":"Effects of intranasal administration of oxytocin and vasopressin on social cognition and potential routes and mechanisms of action","volume":"14","author":"Yao","year":"2022","journal-title":"Pharmaceutics."},{"key":"2024081205561455800_CIT0159","article-title":"Durability of effects of cognitive remediation on cognition and psychosocial functioning in schizophrenia: a systematic review and meta-analysis of randomized clinical trials [published online ahead of print March 13, 2024]","author":"Vita","journal-title":"Am J Psychiatry."},{"issue":"8","key":"2024081205561455800_CIT0160","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1017\/S0033291722000319","article-title":"Acceptability of cognitive remediation for schizophrenia: a systematic review and meta-analysis of randomized controlled trials","volume":"53","author":"Vita","year":"2023","journal-title":"Psychol Med."},{"key":"2024081205561455800_CIT0161","article-title":"Application of cognitive remediation in the world: new experiences from two schizophrenia rehabilitation centers in Togo and Benin [published online ahead of print January 7, 2024]","author":"Deste","journal-title":"Soc Psychiatry Psychiatr Epidemiol."},{"key":"2024081205561455800_CIT0162","doi-asserted-by":"crossref","first-page":"649737","DOI":"10.3389\/fpsyt.2021.649737","article-title":"Effects of cognitive remediation on cognition, metacognition, and social cognition in patients with schizophrenia","volume":"12","author":"Montemagni","year":"2021","journal-title":"Front Psychiatry."},{"issue":"10","key":"2024081205561455800_CIT0163","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.3390\/ijerph17103352","article-title":"Evidence-based integrated intervention in patients with schizophrenia: a Pilot Study of feasibility and effectiveness in a real-world rehabilitation setting","volume":"17","author":"Nibbio","year":"2020","journal-title":"Int J Environ Res Public Health."},{"key":"2024081205561455800_CIT0164","doi-asserted-by":"crossref","first-page":"1182441","DOI":"10.3389\/fpubh.2023.1182441","article-title":"Poverty and inequality in real-world schizophrenia: a national study","volume":"11","author":"Fond","year":"2023","journal-title":"Front Public Health."},{"issue":"1","key":"2024081205561455800_CIT0165","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12916-018-1035-5","article-title":"Ethnic minority inequalities in access to treatments for schizophrenia and schizoaffective disorders: findings from a nationally representative cross-sectional study","volume":"16","author":"Das-Munshi","year":"2018","journal-title":"BMC Med."},{"issue":"2","key":"2024081205561455800_CIT0166","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/0020764013481426","article-title":"Income inequality and schizophrenia: increased schizophrenia incidence in countries with high levels of income inequality","volume":"60","author":"Burns","year":"2014","journal-title":"Int J Soc Psychiatry."},{"issue":"2","key":"2024081205561455800_CIT0167","first-page":"151","article-title":"Combined cognitive training and transcranial direct current stimulation in neuropsychiatric disorders: a systematic review and meta-analysis","volume":"8","author":"Burton","year":"2023","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging."},{"key":"2024081205561455800_CIT0168","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.schres.2020.03.002","article-title":"Targeting cognition in schizophrenia through transcranial direct current stimulation: a systematic review and perspective","volume":"220","author":"Kostova","year":"2020","journal-title":"Schizophr Res."},{"key":"2024081205561455800_CIT0169","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jpsychires.2022.09.011","article-title":"Effects of bilateral, bipolar-nonbalanced, frontal transcranial Direct Current Stimulation (tDCS) on negative symptoms and neurocognition in a sample of patients living with schizophrenia: results of a randomized double-blind sham-controlled trial","volume":"155","author":"Lisoni","year":"2022","journal-title":"J Psychiatr Res."},{"key":"2024081205561455800_CIT0170","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.schres.2019.11.011","article-title":"Effect of multi-session prefrontal transcranial direct current stimulation on cognition in schizophrenia: a systematic review and meta-analysis","volume":"216","author":"Narita","year":"2020","journal-title":"Schizophr Res."},{"issue":"1","key":"2024081205561455800_CIT0171","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1192\/j.eurpsy.2022.2316","article-title":"European Psychiatric Association guidance on assessment of cognitive impairment in schizophrenia","volume":"65","author":"Vita","year":"2022","journal-title":"Eur Psychiatry."}],"container-title":["Schizophrenia Bulletin Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/schizbullopen\/advance-article-pdf\/doi\/10.1093\/schizbullopen\/sgae013\/57834591\/sgae013.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/schizbullopen\/article-pdf\/5\/1\/sgae013\/58797492\/sgae013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/schizbullopen\/article-pdf\/5\/1\/sgae013\/58797492\/sgae013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T02:01:17Z","timestamp":1723428077000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/schizbullopen\/article\/doi\/10.1093\/schizbullopen\/sgae013\/7680105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":171,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/schizbullopen\/sgae013","relation":{},"ISSN":["2632-7899"],"issn-type":[{"value":"2632-7899","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1,1]]},"published":{"date-parts":[[2024,1,1]]},"article-number":"sgae013"}}